Company profile

Aridis Pharmaceuticals

aridispharma.comHeadquarters: United States
11-50 employeesProduct Vendor
Aridis Pharmaceuticals logo

Primary focus

Developing human-derived monoclonal antibody therapeutics and inhaled small-molecule anti-infectives for severe respiratory infections.

Why it’s included

The company develops multiple named monoclonal antibody therapeutics and inhaled small-molecule anti-infectives targeting ESKAPE pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, as evidenced by products like AR-401 and AR-301 and supporting patents and grants.

Relevant capabilities

  • In vitro antibacterial and biofilm activity testing
  • In vivo pulmonary infection models and efficacy testing
  • Clinical trial design and execution (Phase I–III) for respiratory anti-infectives
  • Formulation and inhalation delivery development for small-molecule anti-infectives
  • Discovery of human monoclonal antibodies from convalescent patients
Commercial sectorAntibacterial Biologics & Immunotherapeutics
Technology classesMonoclonal antibodies targeting bacterial pathogens, Antivirulence agents (quorum sensing, toxin, biofilm), Novel antibiotic classes (non-beta-lactam)

Relevant commercial products

  • Panaecin
  • AR-501 (inhaled gallium citrate)
  • AR-401
  • AR-301
  • AR-105

Relevant patents

3 families, 5 publications
  • Gallium formulation for the treatment and prevention of infectious diseases US-8637090-B2
  • Human monoclonal antibody against S. aureus derived alpha-toxin and its use in treating or preventing abscess formation US-9249215-B2
  • Targets of Acinetobacter baumannii US-10098942-B2

← Back to what’s inside this report